Join Catalyst Pharmaceuticals on Wednesday, November 29th, to learn about a new FDA-approved treatment for Duchenne muscular dystrophy. During the session, Catalyst Pharmaceuticals will provide an overview of how this novel corticosteroid works and its efficacy in Duchenne.

You will also learn about the journey to comprehensive support and access through the well-established Catalyst Pathways patient support program.

REGISTER HERE